Table 5. Eribulin and cisplatin plasma pharmacokinetics.
| |
|
|
|
Eribulin mesylate |
Cisplatin |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dose level | Eribulin mesylate dose (mg m−2) | Cisplatin dose (mg m−2) | N | Cmax (μg l−1) | AUC0-inf (μg lx−1 h−1) | CL (l h−1) | Vss(L) | T1/2(h) | Cmax (mg l−1) | AUC0-inf (mg l−1x h−1) |
| Dose level 3 |
1.2 |
60 |
4 |
465.9 (65) |
1499.1 (797) |
1.6 (0.6) |
51.4 (25) |
40.8 (11) |
1.7 (0.7) |
134.1 (11) |
| Dose level 6 |
1.2 |
75 |
3 |
695.1 (5) |
1030.1 (135) |
2.2 (0.2) |
68.4 (27) |
35.5 (5) |
1.6 (0.4) |
92.5 (28) |
| Dose level 5 | 1.4 | 60 | 6 | 508.3 (196) | 1096.8 (335) | 2.3 (0.9) | 77.7 (36) | 36.5 (10) | 2.1 (0.8) | 156.0 (49) |
Abbreviations: AUC=area under the curve; CL=clearance.
Note: Data are mean (s.d.).